



August 26, 2022

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015.**

We are pleased to enclose a Press Release as regards, receipt of approval from MHRA, UK for Lutio® (Tiotropium bromide inhalation powder), to market a generic version of Spiriva®.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**



Encl: a/a

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com

Lupin Announces UK MHRA Approval of Lutio® (Tiotropium bromide inhalation powder) for Treatment of COPD

Mumbai, India | Slough, UK, August 26, 2022: Global pharma major Lupin Limited (Lupin) announced today that its UK subsidiary, Lupin Healthcare (UK) Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a generic version of Spiriva®. Lutio® has the potential to offer significant cost savings when available to UK patients.

“We are pleased to have received the approval of Lutio® from the MHRA for the treatment of chronic obstructive pulmonary disease (COPD), providing an effective and high-quality treatment option to patients in UK,” said **Thierry Volle, President, EMEA, Lupin**.

Tiotropium is used to relieve wheezing, shortness of breath, coughing, and chest tightness in patients with chronic obstructive pulmonary disease (COPD), a group of diseases that affect the lungs and airways) such as chronic bronchitis and emphysema.

This is the second inhalation product by Lupin Healthcare for the UK market after Luforbec® pressurised metered dose inhaler (pMDI).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com

****Safe Harbor Statement***

Spiriva® is a registered trademark of Boehringer Ingelheim Pharma GmbH & Co. KG